BioCryst Pharmaceuticals Continues Forodesine HCl Program In Chronic Lymphocytic Leukemia

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced interim data from the ongoing Forodesine HCl Phase 2 program in patients with chronic lymphocytic leukemia (CLL) and data from a healthy subject pharmacokinetic and pharmacodynamic study. The CLL study will continue with an amendment to study a new dosing regimen of oral Forodesine, 200 mg twice-daily.

More: continued here

Filed under: Pharma Industry on January 3rd, 2009